FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Tho: Margin Disappointment Underpins Earnings Miss; Fy 26 Eps Guidance Cut

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Thor Industries (THO) posted Apr.-Q EPS of $1.86 vs. $2.53 prior year (-27%), well short of the $1.94 consensus. THO's net sales fell 3.9% to $2.78B ($130M ahead of consensus) but gross margin declined 250 bps to 12.8% (230 bps below consensus). Management commented that results reflected suppressed consumer sentiment and cautious dealer ordering patterns, while margin contraction reflected increased material costs and unfavorable product mix. THO maintained prior FY 26 (Jul.) net sales guidance of $9.0B-$9.5B (current consensus: $9.53B), but lowered EPS guidance to $3.30-$3.80 from $3.75-$4.25 previously (consensus: $4.07). Shares are down 8% in pre-market trading. THO said the guidance cut reflects the prolonged nature of current macroeconomic challenges. While we have been concerned about RV demand ever since the oil price spike began a few months ago, THO's top line results were actually a lot better than expected. Instead, margins are where it disappointed, causing the earnings miss and EPS guidance cut.

Related Articles

Research

Goldman Sachs Downgrades ODDITY Tech to Sell From Neutral, Adjusts Price Target to $8 From $16

ODDITY Tech (ODD) has an average rating of hold and mean price target of $12.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ODD
Research

Maxim Downgrades Innovative Eyewear to Hold From Buy

$LUCY
Research

Research Alert: Mdt Posts Solid Fy 26; Margin Pressures Persist, Eps Guidance Disappoints

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:MDT posted Q4 FY 26 (Apr.) revenue of $9.8B (+9.9% reported, +6.6% organic), beating consensus by $194M, while non-GAAP EPS of $1.55 beat the consensus view by $0.01 but declined 4.3% Y/Y. The Cardiovascular Portfolio delivered solid 13.8% Y/Y growth to $3.8B in Q4, led by Cardiac Ablation Solutions sales surging 78% globally, reflecting rapid adoption of pulsed field ablation technologies. However, FY 27 guidance disappointed with non-GAAP EPS of $5.90-$6.00 below consensus at the midpoint of $5.95. Regulatory milestones including FDA submissions for Hugo robotic surgery system and CathWorks acquisition completion could advance growth, in our view. We think the active M&A strategy with Scientia Vascular and SPR Therapeutics acquisitions could complement organic innovation and boost revenues. While MDT could continue solid top-line performance with its robust pipeline and market positions, we believe margin pressures from rising costs, supply chain challenges, and tariffs could negatively impact profitability.

$MDT